PharmaDrug Announces Drug-Repurposing Expert Moshe Rogosnitzky Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board

Mar 9, 2021

Toronto, Ontario – March 9, 2021 – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”) wholly-owned subsidiary, Sairiyo Therapeutics Inc. (“Sairiyo”), a biotechnology company focused on the...

PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board

Mar 4, 2021

Toronto, Ontario – March 4, 2021 –  PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”) wholly-owned subsidiary, Sariyo Therapeutics Inc. (“Sairiyo”), a biotechnology company focused on the...

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

Feb 11, 2021

  Toronto, Ontario – February 11, 2021 – PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...

PharmaDrug Signs Supply Agreement with Global Cannabis Supplier and Provides Update on German Operations and Balance Sheet Improvements

Feb 4, 2021

Toronto, Ontario – February 4, 2021 – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”) has entered into a supply agreement (the “Supply Agreement”) on January 4, 2021, with a Canadian based...

PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.

Feb 2, 2021

Toronto, Ontario – February 2, 2021  – PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and...